cis-/trans-8-(3,4,5-Trimethoxystyryl)coffein | 31377-36-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: cis-/trans-8-(3,4,5-Trimethoxystyryl)coffein
• 英文别名: 1,3,7-trimethyl-8-(3,4,5-trimethoxy-styryl)-3,7-dihydro-purine-2,6-dione；8-(3,4,5-trimethoxystyryl)-1,3,7-trimethylxanthine；(E)-1,3,7-Trimethyl-8-(3,4,5-trimethoxystyryl)-1H-purine-2,6(3H,7H)-dione；1,3,7-trimethyl-8-[2-(3,4,5-trimethoxyphenyl)ethenyl]purine-2,6-dione
• CAS: 31377-36-3
• 化学式: C₁₉H₂₂N₄O₅
• 分子量: 386.407
• InChiKey: KIAYWZXEAJWSGJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  86.1
• 氢给体数：
  0
• 氢受体数：
  6

文献信息

• XANTHINE DERIVATIVE
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP0559893A1

  公开（公告）日：1993-09-15

  A novel xanthine derivative represented by general formula (I), which selectively antagonizes adenosine receptor, and a pharmacologically acceptable salt thereof. In formula (I) R¹ and R² may be the same or different from each other and each represents hydrogen, propyl, butyl or allyl; R³ represents hydrogen or lower alkyl; Y¹ and Y² may be the same or different from each other and each represents hydrogen or methyl; and Z represents (un)substituted phenyl, pyridyl, imidazolyl, furyl or thienyl.

  一种由通式(I)代表的选择性拮抗腺苷受体的新型黄嘌呤衍生物及其药理上可接受的盐。在式 (I) 中，R¹ 和 R² 可以相同或不同，各自代表氢、丙基、丁基或烯丙基；R³ 代表氢或低级烷基；Y¹ 和 Y² 可以相同或不同，各自代表氢或甲基；Z 代表（未）取代的苯基、吡啶基、咪唑基、呋喃基或噻吩基。
• ANTIEPILEPTIC AGENT
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1640007A1

  公开（公告）日：2006-03-29

  (wherein R1, R2 and R3 are the same or different and each represents a hydrogen atom, lower alkyl, lower alkenyl or lower alkynyl; R4 represents cycloalkyl,-(CH2)n-R5 or the above formula (II); and X1 and X2 are the same or different and each represents an oxygen atom or a sulfur atom) An antiepil eptic agent comprising the xanthine derivative represented by the above formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient is provided.

  (其中 R1、R2 和 R3 相同或不同，各自代表氢原子、低级烷基、低级烯基或低级炔基；R4 代表环烷基、-(CH2)n-R5 或上式(II)；X1 和 X2 相同或不同，各自代表氧原子或硫原子）。 本发明提供了一种由上式（I）代表的黄嘌呤衍生物或其药学上可接受的盐作为活性成分的抗癫痫剂。
• Xanthine derivatives for treating neurodegenerative disorders
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1666041A2

  公开（公告）日：2006-06-07

  The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明涉及一种治疗神经退行性疾病的药物，由式（I）代表的黄嘌呤衍生物组成： 或其药学上可接受的盐作为活性成分。
• REMEDIAL AGENT FOR NEURAL DEGENERATION
  申请人：——

  公开号：US20030158214A1

  公开（公告）日：2003-08-21

  The present invention relates to a therapeutic agent for neurodegenerative disorders, comprising a xanthine derivative represented by formula (I): 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明涉及一种治疗神经退行性疾病的药物，由式（I）代表的黄嘌呤衍生物组成： 1 或其药学上可接受的盐作为活性成分。
• Therapeutic agent for eating disorders
  申请人：Hara Takuji

  公开号：US20050176739A1

  公开（公告）日：2005-08-11

  The present invention provides a therapeutic agent for eating disorders, comprising, as an active ingredient, a xanthine derivative represented by formula (I): wherein R 1 , R 2 and R 3 independently represent hydrogen, lower alkyl, lower alkenyl or lower alkynyl; R 4 represents cycloalkyl, —(CH 2 ) n —R 5 or the like; and X 1 and X 2 independently represent O or S, or a pharmaceutically acceptable salt thereof.

  本发明提供了一种治疗进食障碍的药物，其活性成分包括由式(I)表示的黄嘌呤衍生物： 其中 R 1 , R 2 和 R 3 分别代表氢、低级烷基、低级烯基或低级炔基； R 4 代表环烷基、-(CH 2 ) n -R 5 或类似；以及 X 1 和 X 2 分别代表 O 或 S，或其药学上可接受的盐。